Wall Street placed a $500 million bet on Ripple in November, lifting the company to a $40 billion valuation. The deal locked in protections that gave investors the right to sell shares back at set returns and jump ahead of other owners if Ripple is sold or fails. The buyers in this $500 million deal were […]Wall Street placed a $500 million bet on Ripple in November, lifting the company to a $40 billion valuation. The deal locked in protections that gave investors the right to sell shares back at set returns and jump ahead of other owners if Ripple is sold or fails. The buyers in this $500 million deal were […]

Ripple becomes Wall Street’s favorite crypto bet with $500M financing deal

2025/12/08 20:45
3 min read

Wall Street placed a $500 million bet on Ripple in November, lifting the company to a $40 billion valuation. The deal locked in protections that gave investors the right to sell shares back at set returns and jump ahead of other owners if Ripple is sold or fails.

The buyers in this $500 million deal were Citadel and Fortress Investment, joined by funds tied to Marshall Wace, Brevan Howard, Galaxy Digital, and Pantera Capital.

For some backers, the bet was not on software or payment rails but on XRP itself. Two funds in the round calculated that at least 90% of Ripple’s net asset value came from the token.

As of July, the company held $124 billion worth of XRP, much of it under lockups and slow release schedules. Since October 31, XRP has slid about 16%, and it is down more than 40% from its mid-July peak during the worst market drop since 2022.

Ripple’s investors are demanding payouts and control

Under the contract, investors won the option to sell their shares back to Ripple after three or four years at a 10% annual return, unless the company lists first. Ripple can also force a buyback at those windows, but doing so requires a 25% annual return.

Kyle Stanford, director of U.S. venture capital research at PitchBook, said these put options are rare and show up more with non‑traditional venture firms.

Kyle warned that such structures can push companies to burn cash or raise new funding to clear investor rights and shrink money for daily operations. A full four‑year buyback would cost Ripple about $732 million.

Those terms now sit beside rate swings as desks price exit risk into models each quarter. Banks track the clocks closely now. Across all desks.

Deals widen reach as market tests patience

The Ripple sale landed in a year when crypto firms raised about $23 billion through venture rounds and IPOs as Donald Trump returned to the White House.

That figure does not include Tether, which is seeking up to $20 billion and has held talks with SoftBank Group Corp. and Ark Investment Management. Shares of firms that listed in 2025, including Circle Internet Group and several crypto accumulation vehicles, fell hard in recent months.

American Bitcoin Corp., co-founded by Eric Trump, dropped more than 50% within minutes on December 2. Inside Ripple, Monica Long, the company’s president, said in November there is “no plan, no timeline” for an IPO. The firm also confirmed it has repurchased more than 25% of its outstanding shares.

Unlike Binance and Coinbase, which depend on trading volume, or Tether, which earns on reserves behind its $185 billion USDT, much of Ripple’s value still comes from the XRP it controls. In April, Ripple agreed to buy Hidden Road for $1.25 billion.

In October, it followed with a $1 billion deal for GTreasury. One investor executive said the XRP stash makes up almost the full valuation. Another person said Citadel disagreed.

Even after the selloff, Ripple’s XRP holdings were still worth about $83.3 billion as of Sunday, assuming token levels stayed steady since July 31. Prices still swing across desks as traders track exposure daily now.

If you're reading this, you’re already ahead. Stay there with our newsletter.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26